Subscribe To

Price Alert Latest News Economic Calendar News

VPHIF / Valeo Pharma raises Q4 and FY2022 revenue guidance to record levels

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has raised its revenue guidance for the fourth quarter of 2022 by 14%-18% to a record $12.5-$13.0 million, and its fiscal 2022 revenue guidance to $27.5-$28.0 million, also a record and more than double the actual 2021 revenue of $13.6 million. The higher guidance is spurred by the continued growth of its asthma therapies Enerzair Breezhaler and Atectura Breezhaler and the low molecular weight heparin biosimilar REDESCA, as well as the additional revenues generated in the fourth quarter by the recently-added ophthalmology products XIIDRA, SIMBRINZA, and the epinephrine auto-injector ALLERJECT, the pharmaceutical company said. Read More

Demo Live Account See Partner Details

Content Topics

Valeo

Pharma

Raises

Fy2022

Revenue

Guidance

Record

Levels

Stock

VPHIF

Posted: Nov 15 2022, 08:43

Author Name: Proactive Investors

VPHIF News

By Proactive Investors
October 5, 2023

Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an

By Proactive Investors
October 4, 2023

Valeo Pharma secures spot on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis

By Proactive Investors
September 14, 2023

Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz

By Proactive Investors
September 1, 2023

Valeo Pharma raises funds totalling $4.5M

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a

By Proactive Investors
June 22, 2023

Valeo Pharma bolsters board with two new directors

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo

By Proactive Investors
June 14, 2023

Valeo Pharma reports record quarterly revenues

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr

By Proactive Investors
May 25, 2023

Valeo Pharma expects 2Q revenues to set quarterly record

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex

By Proactive Investors
March 16, 2023

Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.